Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed ...

The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

The treatment of cancer involves different strategies, such as chemotherapy, surgery, radiation therapy and, most recently, targeted therapies, such as the use of radionuclide-based therapies employed ...

CHENGDU, China, March 25, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the ...

Radionuclide therapy is changing dynamically. Monoclonal antibody therapies for non-Hodgkins lymphoma using iodine-131; or imaging with indium-111, followed with yttrium-90 for the therapy are the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The VISION ...

Decommissioning, Decontamination, and Technique Development During nuclear decommissioning, radionuclide contaminated materials need to be accurately identified and sentenced for disposal as ...

Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the ...